StockData
IGC Pharma, Inc. logo

IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+3.57%)

Close on Nov 18, 2026Market cap $20.12MP/E –Yield –

IGC Pharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

IGC Pharma's free cash flow for the twelve months ending Mar 31, 2026 was -$5.99M. For fiscal 2025 it was -$4.91M. The highest annual figure on record is $238.77K in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Mar 31, 2025-$4.91M–
FY2024Mar 31, 2024-$5.34M–
FY2023Mar 31, 2023-$7.36M–
FY2022Mar 31, 2022-$7.70M–
FY2021Mar 31, 2021-$12.27M–
FY2020Mar 31, 2020-$13.07M–
FY2019Mar 31, 2019-$3.35M–
FY2018Mar 31, 2018-$2.07M–
FY2017Mar 31, 2017-$1.54M–
FY2016Mar 31, 2016-$279.89K–
FY2015Mar 31, 2015-$2.66M–
FY2014Mar 31, 2014-$1.75M-833.2%
FY2013Mar 31, 2013$238.77K–
FY2012Mar 31, 2012-$5.03M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ1 2026Mar 31, 2026-$1.22M–
Q3 FY2026CQ4 2025Dec 31, 2025-$1.24M–
Q2 FY2026CQ3 2025Sep 30, 2025-$2.12M–
Q1 FY2026CQ2 2025Jun 30, 2025-$1.42M–
Q4 FY2025CQ1 2025Mar 31, 2025-$748.00K–
Q3 FY2025CQ4 2024Dec 31, 2024-$1.34M–
Q2 FY2025CQ3 2024Sep 30, 2024-$1.03M–
Q1 FY2025CQ2 2024Jun 30, 2024-$1.79M–
Q4 FY2024CQ1 2024Mar 31, 2024-$541.00K–
Q3 FY2024CQ4 2023Dec 31, 2023-$1.66M–
Q2 FY2024CQ3 2023Sep 30, 2023-$1.65M–
Q1 FY2024CQ2 2023Jun 30, 2023-$1.49M–
Q1 FY2023CQ2 2022Jun 30, 2022-$2.32M–
Q4 FY2022CQ1 2022Mar 31, 2022-$971.00K–
Q3 FY2022CQ4 2021Dec 31, 2021-$2.45M–
Q2 FY2022CQ3 2021Sep 30, 2021-$2.33M–
Q1 FY2022CQ2 2021Jun 30, 2021-$1.94M–
Q4 FY2021CQ1 2021Mar 31, 2021-$2.59M–
Q3 FY2021CQ4 2020Dec 31, 2020-$2.00M–
Q2 FY2021CQ3 2020Sep 30, 2020-$2.75M–
Q1 FY2021CQ2 2020Jun 30, 2020-$4.93M–
Q4 FY2020CQ1 2020Mar 31, 2020-$2.71M–
Q3 FY2020CQ4 2019Dec 31, 2019-$3.87M–
Q2 FY2020CQ3 2019Sep 30, 2019-$2.45M–
Q1 FY2020CQ2 2019Jun 30, 2019-$4.05M–
Q4 FY2019CQ1 2019Mar 31, 2019-$1.16M–
Q3 FY2019CQ4 2018Dec 31, 2018-$1.34M–
Q2 FY2019CQ3 2018Sep 30, 2018-$316.00K–
Q1 FY2019CQ2 2018Jun 30, 2018-$538.00K–
Q4 FY2018CQ1 2018Mar 31, 2018-$1.08M–
Q3 FY2018CQ4 2017Dec 31, 2017-$348.00K-601.4%
Q2 FY2018CQ3 2017Sep 30, 2017-$110.22K–
Q1 FY2018CQ2 2017Jun 30, 2017-$525.78K–
Q4 FY2017CQ1 2017Mar 31, 2017-$924.92K–
Q3 FY2017CQ4 2016Dec 31, 2016$69.40K–
Q2 FY2017CQ3 2016Sep 30, 2016-$881.03K–

More IGC Pharma figures

See a number that looks wrong?